Clinics in Louisiana

By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified Sep 27, 2026

What Louisiana law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and verified listings.

Louisiana at a glance

Pharmacy regulator: Louisiana Board of Pharmacy
503A framework: Follows the federal 503A framework
Telehealth prescribing: Regulatory: Telehealth allowed
Asynchronous prescribing: Regulatory: Async not allowed
Compounded GLP-1 access: Regulatory: Compounded GLP-1 limited

Verified clinics serving Louisiana

No verified clinics serving Louisiana are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in Louisiana

Yes. A Louisiana resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a physician licensed to practice medicine or telemedicine in Louisiana under La. R.S. 37:1271, and a physician with an unrestricted Louisiana license does not need an in-person exam before a telemedicine visit for non-controlled drugs. For obesity treatment and weight management, Act 345 of 2026 requires a synchronous (live) interaction with the patient. Compounded peptides are available when eligible under federal 503A rules and dispensed by a Louisiana pharmacy or a nonresident pharmacy holding a Louisiana Board of Pharmacy permit (La. R.S. 37:1232). The Louisiana Board of Pharmacy was one of the first boards, in 2023, to tell pharmacies to stop compounding with semaglutide salt forms and to stop shipping such products into the state. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [18]

Compounded GLP-1 access in Louisiana

In spring 2023, while semaglutide was still in shortage, the Louisiana Board of Pharmacy told in-state compounders to stop compounding semaglutide made from unapproved salt forms (such as semaglutide sodium or acetate) and told out-of-state compounders not to ship such products into Louisiana; the Board's director clarified that compounding with the approved base form was not banned at the time. Since the FDA shortage allowances ended in 2025, compounded semaglutide and tirzepatide are limited to documented patient-specific needs in Louisiana as elsewhere. Telehealth weight management programs serving Louisiana patients must use a live, synchronous interaction under Act 345 of 2026. [1] [11] [12] [16]

Research use only sellers in Louisiana

Only Louisiana-permitted pharmacies, including nonresident pharmacies permitted under La. R.S. 37:1232, may dispense prescription drugs to Louisiana patients. The Louisiana Board of Pharmacy has described semaglutide salt forms sold as "research use only" as not intended for human use, and "research use only" peptides sold for injection are unapproved new drugs under federal law. [5] [12] [17]

Louisiana notes on specific peptides

Semaglutide: Available branded by prescription. The Louisiana Board of Pharmacy warned in 2023 against compounding with semaglutide salt forms and against shipping such products into Louisiana, and compounded semaglutide base is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025. [12] [16]
Tirzepatide: Available branded by prescription, including by telemedicine from a physician with a Louisiana license or telemedicine license. Compounded tirzepatide is limited to documented patient-specific needs since the 503A grace period ended February 18, 2025. [3] [16]
BPC-157: Not FDA approved and not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk; a state board cannot authorize what federal law does not. The Louisiana Board of Pharmacy has not issued a BPC-157 specific rule, and its stated position is that compounders may use only bulk substances that meet federal requirements. Act 374 of 2026 (La. R.S. 37:23.5) bars Louisiana licensing boards from prohibiting peptide compounding that complies with section 503A, but BPC-157 is still not eligible under 503A until FDA adds it to the bulks list. [12] [14] [15] [18]

How to check a clinic in Louisiana

Confirm the prescribing clinician's license with the Louisiana medical or nursing board.
Ask which pharmacy compounds or dispenses the peptide and check it in the Louisiana Board of Pharmacy license lookup. [1] [5] [6] [7] [8] [9] [12] [13] [18]
Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Louisiana. [5] [12] [17]

Common questions in Louisiana

Does Louisiana let out-of-state doctors prescribe by telemedicine?

Only with Louisiana authorization. La. R.S. 37:1271 requires a license to practice medicine or telemedicine in Louisiana, and Louisiana issues telemedicine licenses to qualifying physicians licensed in other states. Check the Louisiana State Board of Medical Examiners lookup. [2] [3]

Do I need an in-person visit before a telemedicine GLP-1 prescription in Louisiana?

Not if the physician holds an unrestricted Louisiana license. La. R.S. 37:1271 says such a physician is not required to do an in-person history or exam before a telemedicine encounter, though the same standard of care applies. The in-person requirement applies to controlled dangerous substances, and GLP-1 drugs are not controlled. When the prescription is for obesity or weight management, Act 345 of 2026 requires the provider to conduct a live, synchronous interaction with you; a questionnaire or message exchange alone is not enough. [3] [4] [11]

All peptide legal questions for Louisiana